Wedbush Comments on Stemline Therapeutics Inc.’s Q3 2017 Earnings (STML)
Stemline Therapeutics Inc. (NASDAQ:STML) – Analysts at Wedbush dropped their Q3 2017 earnings per share estimates for shares of Stemline Therapeutics in a research note issued to investors on Tuesday. Wedbush analyst D. Nierengarten now forecasts that the firm will post earnings per share of ($0.40) for the quarter, down from their prior estimate of ($0.39). Wedbush has a “Outperform” rating and a $15.00 price target on the stock. Wedbush also issued estimates for Stemline Therapeutics’ Q4 2017 earnings at ($0.54) EPS, FY2017 earnings at ($1.93) EPS and FY2018 earnings at ($0.97) EPS.
Other research analysts have also recently issued research reports about the stock. Roth Capital restated a “buy” rating and issued a $32.00 target price on shares of Stemline Therapeutics in a report on Friday. Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. Finally, Jefferies Group restated a “buy” rating on shares of Stemline Therapeutics in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $20.50.
Shares of Stemline Therapeutics (NASDAQ:STML) opened at 12.25 on Friday. The firm’s market cap is $218.36 million. The stock has a 50 day moving average of $11.66 and a 200 day moving average of $8.43. Stemline Therapeutics has a 12 month low of $3.88 and a 12 month high of $14.20.
Hedge funds have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Stemline Therapeutics during the first quarter valued at approximately $232,000. Carl Domino Inc increased its stake in Stemline Therapeutics by 12.9% in the second quarter. Carl Domino Inc now owns 26,305 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,000 shares during the period. California State Teachers Retirement System increased its stake in Stemline Therapeutics by 6.1% in the second quarter. California State Teachers Retirement System now owns 35,349 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 2,019 shares during the period. Emerald Acquisition Ltd. acquired a new stake in Stemline Therapeutics during the second quarter valued at approximately $129,000. Finally, Nationwide Fund Advisors increased its stake in Stemline Therapeutics by 63.2% in the second quarter. Nationwide Fund Advisors now owns 22,395 shares of the biopharmaceutical company’s stock valued at $152,000 after buying an additional 8,670 shares during the period. Hedge funds and other institutional investors own 52.60% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.